Moderna, Merck say vaccine improved survival in patients with deadly skin cancer

Moderna and Merck released more positive three-year data Monday on their experimental vaccine, given to patients with the most deadly form of skin cancer in combination with the therapy Keytruda. The vaccine together with Merck's Keytruda improved survival and showed long-lasting efficacy in a midstage study in patients with a deadly form of skin cancer. Moderna and Merck are presenting the data at the American Society of Clinical Oncology annual meeting in Chicago. The shot is a key part of Moderna's pipel ...